LILLY-I4T-IE-JVBD

Study Sponsor: Lilly

Study Title

A Phase 3, Randomized, Double-Blinded Study of IMC-1121B and Best Supportive Care (BSC) Versus Placebo and BSC in the Treatment of Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Following Disease Progression on First-Line Platinum- or Fluoropyrimidine-Containing Combination Therapy

Medicine or Vaccine (generic name)

Ramucirumab

Sponsor Identification Number

I4T-IE-JVBD

Trial Registry Identification Number(#'s)

NCT00917384

Medical Condition

Gastric Cancer

Phase

Phase 3

Link to study details on the Lilly Clinical Study Register

Link to study details on ClinicalTrials.gov (if available)

https://clinicaltrials.gov/ct2/show/study/NCT00917384?term=I4T-IE-JVBD&rank=1

Link to study details on EudraCT (if available)

Not available

Datasets and Documents Available for this Study

Raw dataset	Annotated case report form	Dataset specifications	Protocol with any amendments
Analysis-ready dataset	Reporting and analysis plan	Clinical study report	Ready to Share

Additional information about the data and documents available for this study

Date Added to this Site

November 2015